Drug resistance: Still a daunting challenge to the successful treatment of AML

Drug Resistance Updates

Volumn 15, Issue 1-2, 2012, Pages 62-69

  Shaffer, Brian C ^a   Gillet, Jean Pierre ^a   Patel, Chirayu ^a   Baer, Maria R ^b   Bates, Susan E ^a   Gottesman, Michael M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

Author keywords

ABC transporters; Acute myeloid leukemia; Cancer stem cells; Gene signatures; Multidrug resistance

Indexed keywords

ABC TRANSPORTER; CYCLOSPORIN A; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; GLYCOPROTEIN P; IDARUBICIN; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN; QUININE; VALSPODAR; ZOSUQUIDAR;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER RESISTANCE; CANCER STEM CELL; CELL MEMBRANE TRANSPORT; CELL PROLIFERATION; DOWN REGULATION; EPIGENETICS; HUMAN; MULTIDRUG RESISTANCE; MYELOID PROGENITOR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84860689257     PISSN: 13687646     EISSN: 15322084     Source Type: Journal    
DOI: 10.1016/j.drup.2012.02.001     Document Type: Article

References (88)

1. B.L. Abbott, A.M. Colapietro, Y. Barnes, F. Marini, M. Andreeff, and B.P. Sorrentino Low levels of ABCG2 expression in adult AML blast samples Blood 100 2002 4594 4601
2. K. Anderson, C. Lutz, F.W. van Delft, C.M. Bateman, Y. Guo, and S.M. Colman Genetic variegation of clonal architecture and propagating cells in leukaemia Nature 469 2011 356 361
3. A. Apáti, T.I. Orbán, N. Varga, A. Németh, A. Schamberger, and V. Krizsik High level functional expression of the ABCG2 multidrug transporter in undifferentiated human embryonic stem cells Biochim. Biophys. Acta 1778 2008 2700 2709
4. U. Bacher, T. Haferlach, T. Alpermann, M. Zenger, N. Kröger, and D.W. Beelen Comparison of cytogenetic clonal evolution patterns following allogeneic hematopoietic transplantation versus conventional treatment in patients at relapse of AML Biol. Blood Marrow Transplant. 16 2010 1649 1657
5. M.R. Baer, S.L. George, R.K. Dodge, K.L. O'Loughlin, H. Minderman, and M.A. Caligiuri Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: cancer and leukemia group B study 9720 Blood 100 2002 1224 1232
6. S.E. Bates, S. Bakke, M. Kang, R.W. Robey, S. Zhai, and P. Thambi A phase I/II study of infusional vinblastine with the P-glycoprotein antagonist valspodar (PSC 833) in renal cell carcinoma Clin. Cancer Res. 10 2004 4724 4733
7. Z. Benderra, A.M. Faussat, L. Sayada, J.Y. Perrot, D. Chaoui, and J.P. Marie Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias Clin. Cancer Res. 10 2004 7896 7902
8. Z. Benderra, A.M. Faussat, L. Sayada, J.Y. Perrot, R. Tang, and D. Chaoui MRP3, BCRP, and P-glycoprotein activities are prognostic factors in adult acute myeloid leukemia Clin. Cancer Res. 11 2005 7764 7772
9. M. Bhatia, J.C. Wang, U. Kapp, D. Bonnet, and J.E. Dick Purification of primitive human hematopoietic cells capable of repopulating immune-deficient mice Proc. Natl. Acad. Sci. U.S.A. 94 1997 5320 5325
10. E.E. Bram, M. Stark, S. Raz, and Y.G. Assaraf Chemotherapeutic drug-induced ABCG2 promoter demethylation as a novel mechanism of acquired multidrug resistance Neoplasia 11 2009 1359 1370
11. K.D. Bunting, S. Zhou, T. Lu, and B.P. Sorrentino Enforced P-glycoprotein pump function in murine bone marrow cells results in expansion of side population stem cells in vitro and repopulating cells in vivo Blood 96 2000 902 909
12. I. Cascorbi, and S. Haenisch Pharmacogenetics of ATP-binding cassette transporters and clinical implications Methods Mol. Biol. 596 2010 95 121
13. B. Chapuy, R. Koch, U. Radunski, S. Corsham, N. Cheong, and N. Inagaki Intracellular ABC transporter A3 confers multidrug resistance in leukemia cells by lysosomal drug sequestration Leukemia 22 2008 1576 1586
14. P.M. Chaudhary, and I.B. Roninson Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells Cell 66 1991 85 94
15. S. Cole, G. Bhardwaj, J. Gerlach, J. Mackie, C. Grant, and K. Almquist Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line Science 258 1992 1650 1654
16. C. Cordon-Cardo, J.P. O'Brien, J. Boccia, D. Casals, J.R. Bertino, and M.R. Melamed Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues J. Histochem. Cytochem. 38 1990 1277 1287
17. A. Cozzio, E. Passegue, P.M. Ayton, H. Karsunky, M.L. Cleary, and I.L. Weissman Similar MLL-associated leukemias arising from self-renewing stem cells and short-lived myeloid progenitors Genes Dev. 17 2003 3029 3035
18. L.D. Cripe, H. Uno, E.M. Paietta, M.R. Litzow, R.P. Ketterling, and J.M. Bennett Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999 Blood 116 2010 4077 4085
19. D. Damiani, M. Tiribelli, E. Calistri, A. Geromin, A. Chiarvesio, and A. Michelutti The prognostic value of P-glycoprotein (ABCB) and breast cancer resistance protein (ABCG2) in adults with de novo acute myeloid leukemia with normal karyotype Haematologica 91 2006 825 828
20. D. Damiani, M. Tiribelli, D. Raspadori, A. Michelutti, A. Gozzetti, and E. Calistri The role of MDR-related proteins in the prognosis of adult acute myeloid leukaemia (AML) with normal karyotype Hematol. Oncol. 25 2007 38 43
21. L.A. Doyle, W. Yang, L.V. Abruzzo, T. Krogmann, Y. Gao, and A.K. Rishi A multidrug resistance transporter from human MCF-7 breast cancer cells Proc. Natl. Acad. Sci. U.S.A. 95 1998 15665 15670
22. K.L. Fung, and M.M. Gottesman A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function BBA-Proteins Proteom. 1794 2009 860 871
23. G. Gerrard, E. Payne, R. Baker, D. Jones, M. Potter, and H. Prentice Clinical effects and P-glycoprotein inhibition in patients with acute myeloid leukemia treated with zosuquidar trihydrochloride, daunorubicin and cytarabine Haematologica 89 2004 782 790
24. J.-P. Gillet, T. Efferth, and J. Remacle Chemotherapy-induced resistance by ATP-binding cassette transporter genes BBA-Rev. Cancer 1775 2007 237 262
25. P.B. Gupta, C.L. Chaffer, and R.A. Weinberg Cancer stem cells: mirage or reality? Nat. Med. 15 2009 1010 1012
26. P.L. Greenberg, S.J. Lee, R. Advani, M.S. Tallman, B.I. Sikic, and L. Letendre Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995) J. Clin. Oncol. 22 2004 1078 1086
27. P.B. Gupta, T.T. Onder, G. Jiang, K. Tao, C. Kuperwasser, and R.A. Weinberg Identification of selective inhibitors of cancer stem cells by high-throughput screening Cell 138 2009 645 659
28. S.S. Hampras, L. Sucheston, J. Weiss, M.R. Baer, G. Zirpoli, and P.K. Singh Genetic polymorphisms of ATP-binding cassette (ABC) proteins, overall survival and drug toxicity in patients with Acute Myeloid Leukemia Int. J. Mol. Epidemiol. Genet. 1 2010 201 207
29. K. Han, J. Kahng, M. Kim, J. Lim, Y. Kim, and B. Cho Expression of functional markers in acute nonlymphoblastic leukemia Acta Haematol. 104 2000 174 180
30. K.M. Hatle, W. Neveu, O. Dienz, S. Rymarchyk, R. Barrantes, and S. Hale Methylation-controlled J protein promotes c-Jun degradation to prevent ABCB1 transporter expression Mol. Cell. Biol. 27 2007 2952 2966
31. C.J. Hess, A. Errami, J. Berkhof, F. Denkers, G.J. Ossenkoppele, and A.O. Nygren Concurrent methylation of promoters from tumor associated genes predicts outcome in acute myeloid leukemia Leuk. Lymphoma 49 2008 1132 1141
32. K. Honoki Do stem-like cells play a role in drug resistance of sarcomas? Expert Rev. Anticancer Ther. 10 2010 261 270
33. B.J. Huntly, H. Shigematsu, K. Deguchi, B.H. Lee, S. Mizuno, and N. Duclos MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors Cancer Cell 6 2004 587 596
34. R.L. Juliano, and V. Ling A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants Biochim. Biophys. Acta 455 1976 152 162
35. D.H. Kim, J.Y. Park, S.K. Sohn, N.Y. Lee, J.H. Baek, and S.B. Jeon Multidrug resistance-1 gene polymorphisms associated with treatment outcomes in de novo acute myeloid leukemia Int. J. Cancer 118 2006 2195 2201
36. C. Kimchi-Sarfaty, J.M. Oh, I.W. Kim, Z.E. Sauna, A.M. Calcagno, and S.V. Ambudkar A "silent" polymorphism in the MDR1 gene changes substrate specificity Science 315 2007 525 528
37. J.E. Kolitz, S.L. George, R.K. Dodge, D.D. Hurd, B.L. Powell, and S.L. Allen Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of cancer and leukemia group B study 9621 J. Clin. Oncol. 22 2004 4290 4301
38. J.E. Kolitz, S.L. George, G. Marcucci, R. Vij, B.L. Powell, and S.L. Allen P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: cancer and leukemia group B study 19808 Blood 116 2010 1413 1421
39. S. Kornblau, E. Estey, T. Madden, H. Tran, S. Zhao, and U. Consoli Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia J. Clin. Oncol. 15 1997 1796 1802
40. A.V. Krivtsov, D. Twomey, Z. Feng, M.C. Stubbs, Y. Wang, and J. Faber Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9 Nature 442 2006 818 822
41. J.E. Lancet, M.R. Baer, G.E. Duran, A.F. List, R. Fielding, and J.F. Marcelletti A phase I trial of continuous infusion of the multidrug resistance inhibitor zosuquidar with daunorubicin and cytarabine in acute myeloid leukemia Leuk. Res. 33 2009 1055 1061
42. T. Lapidot, C. Sirard, J. Vormoor, B. Murdoch, T. Hoang, and J. Caceres-Cortes A cell initiating human acute myeloid leukaemia after transplantation into SCID mice Nature 367 1994 645 648
43. B. Laupeze, L. Amiot, B. Drenou, M. Bernard, B. Branger, and J.M. Grosset High multidrug resistance protein activity in acute myeloid leukaemias is associated with poor response to chemotherapy and reduced patient survival Br. J. Haematol. 116 2002 834 838
44. C. Leith Multidrug resistance in leukemia Curr. Opin. Hematol. 5 1998 287 291
45. C.P. Leith, K.J. Kopecky, I.M. Chen, L. Eijdems, M.L. Slovak, and T.S. McConnell Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology group study Blood 94 1999 1086 1099
46. K.K. Lin, and M.A. Goodell Purification of hematopoietic stem cells using the side population Methods Enzymol. 420 2006 255 264
47. A.F. List, K.J. Kopecky, C.L. Willman, D.R. Head, D.L. Persons, and M.L. Slovak Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study Blood 98 2001 3212 3220
48. J.A. Liu Yin, K. Wheatley, J.K. Rees, and A.K. Burnett Comparison of 'sequential' versus 'standard' chemotherapy as re-induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (AML): results of the UK Medical Research Council AML-R trial Br. J. Haematol. 113 2001 713 726
49. J. Marie, and O. Legrand MDR1/P-GP expression as a prognostic factor in acute leukemias Adv. Exp. Med. Biol. 457 1999 1 9
50. C. Marzac, E. Garrido, R. Tang, F. Fava, P. Hirsch, and C. De Benedictis ATP binding cassette transporters associated with chemoresistance: transcriptional profiling in extreme cohorts, and their prognostic impact in a cohort of 281 acute myeloid leukemia patients Haematologica 96 2011 1293 1301
51. P. Matsouka, M. Pagoni, P. Zikos, N. Giannakoulas, I. Apostolidis, and T. Asprogeraka Addition of cyclosporin-A to chemotherapy in secondary (post-MDS) AML in the elderly. A multicenter randomized trial of the Leukemia Working Group of the Hellenic Society of Hematology Ann. Hematol. 85 2006 250 256
52. - population Blood 109 2007 543 545
53. M. Michieli, D. Damiani, A. Ermacora, P. Masolini, D. Raspadori, and G. Visani P-glycoprotein, lung resistance-related protein and multidrug resistance associated protein in de novo acute non-lymphocytic leukaemias: biological and clinical implications Br. J. Haematol. 104 1999 328 335
54. M. Nakayama, M. Wada, T. Harada, J. Nagayama, H. Kusaba, and K. Ohshima Hypomethylation status of CpG sites at the promoter region and overexpression of the human MDR1 gene in acute myeloid leukemias Blood 92 1998 4296 4307
55. M. Pallis, J. Turzanski, Y. Higashi, and N. Russell P-glycoprotein in acute myeloid leukaemia: therapeutic implications of its association with both a multidrug-resistant and an apoptosis-resistant phenotype Leuk. Lymphoma 43 2002 1221 1228
56. R. Pirker, J. Wallner, K. Geissler, W. Linkesch, O.A. Haas, and P. Bettelheim MDR1 gene expression and treatment outcome in acute myeloid leukemia J. Natl. Cancer Inst. 83 1991 708 712
57. D. Pulte, A. Gondos, and H. Brenner Expected long-term survival of patients diagnosed with acute myeloblastic leukemia during 2006-2010 Ann. Oncol. 21 2010 335 341
58. M. Qadir, K.L. O'Loughlin, S.M. Fricke, N.A. Williamson, W.R. Greco, and H. Minderman Cyclosporin A is a broad-spectrum multidrug resistance modulator Clin. Cancer Res. 11 2005 2320 2326
59. M. Schaich, S. Soucek, C. Thiede, G. Ehninger, and T. Illmer MDR1 and MRP1 gene expression are independent predictors for treatment outcome in adult acute myeloid leukaemia Br. J. Haematol. 128 2005 324 332
60. C.W. Scharenberg, M.A. Harkey, and B. Torok-Storb The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors Blood 99 2002 507 512
61. C.H. Seedhouse, M. Grundy, P. White, Y. Li, J. Fisher, and D. Yakunina Sequential influences of leukemia-specific and genetic factors on P-glycoprotein expression in blasts from 817 patients entered into the National Cancer Research Network acute myeloid leukemia 14 and 15 trials Clin. Cancer Res. 13 2007 7059 7066
62. J.L. Shipley, and J.N. Butera Acute myelogenous leukemia Exp. Hematol. 37 2009 649 658
63. E. Solary, B. Drenou, L. Campos, P. de Cremoux, F. Mugneret, and P. Moreau Quinine as a multidrug resistance inhibitor: a phase 3 multicentric randomized study in adult de novo acute myelogenous leukemia Blood 102 2003 1202 1210
64. E. Solary, B. Witz, D. Caillot, P. Moreau, B. Desablens, and J.Y. Cahn Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: a randomized multicenter study Blood 88 1996 1198 1205
65. D. Steinbach, J.P. Gillet, A. Sauerbrey, B. Gruhn, K. Dawczynski, and V. Bertholet ABCA3 as a possible cause of drug resistance in childhood acute myeloid leukemia Clin. Cancer Res. 12 2006 4357 4363
66. D. Steinbach, and O. Legrand ABC transporters and drug resistance in leukemia: was P-gp nothing but the first head of the Hydra? Leukemia 21 2007 1172 1176
67. A. Suvannasankha, H. Minderman, K.L. O'Loughlin, T. Nakanishi, W.R. Greco, and D.D. Ross Breast cancer resistance protein (BCRP/MXR/ABCG2) in acute myeloid leukemia: discordance between expression and function Leukemia 18 2004 1252 1257
68. Y. Tabe, M. Konopleva, R. Contractor, M. Munsell, W.D. Schober, and L. Jin Up-regulation of MDR1 and induction of doxorubicin resistance by histone deacetylase inhibitor depsipeptide (FK228) and ATRA in acute promyelocytic leukemia cells Blood 107 2006 1546 1554
69. M. Tiribelli, A. Geromin, A. Michelutti, M. Cavallin, A. Pianta, and D. Fabbro Concomitant ABCG2 overexpression and FLT3-ITD mutation identify a subset of acute myeloid leukemia patients at high risk of relapse Cancer 117 2011 2156 2162
70. T. Tsuruo, H. Iida, S. Tsukagoshi, and Y. Sakurai Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil Cancer Res. 41 1981 1967 1972
71. K. Ueda, D.P. Clark, C.J. Chen, I.B. Roninson, M.M. Gottesman, and I. Pastan The human multidrug resistance (mdr1) gene. cDNA cloning and transcription initiation J. Biol. Chem. 262 1987 505 508
72. J. Utikal, J.M. Polo, M. Stadtfeld, N. Maherali, W. Kulalert, and R.M. Walsh Immortalization eliminates a roadblock during cellular reprogramming into iPS cells Nature 460 2009 1145 1148
73. F.W. van Delft, S. Horsley, S. Colman, K. Anderson, C. Bateman, and H. Kempski Clonal origins of relapse in ETV6-RUNX1 acute lymphoblastic leukemia Blood 117 2011 6247 6254
74. M.M. van den Heuvel-Eibrink, B. van der Holt, A.K. Burnett, W.U. Knauf, M.F. Fey, and G.E. Verhoef CD34-related coexpression of MDR1 and BCRP indicates a clinically resistant phenotype in patients with acute myeloid leukemia (AML) of older age Ann. Hematol. 86 2007 329 337
75. M.M. van den Heuvel-Eibrink, B. van der Holt, and P. Sonneveld Role of BCRP and its expression with MDR1 in adult AML Leuk. Res. 29 2005 115
76. B. van der Holt, B. Lowenberg, A.K. Burnett, W.U. Knauf, J. Shepherd, and P.P. Piccaluga The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis Blood 106 2005 2646 2654
77. B. van der Holt, M.M. Van den Heuvel-Eibrink, R.H.N. Van Schaik, I.P. van der Heiden, E.A.C. Wiemer, and P.J.M. Vossebeld ABCB1 gene polymorphisms are not associated with treatment outcome in elderly acute myeloid leukemia patients[ast] Clin. Pharmacol. Ther. 80 2006 427 439
78. D.M. van der Kolk, E.G. de Vries, L. Noordhoek, E. van den Berg, M.A. van der Pol, and M. Muller Activity and expression of the multidrug resistance proteins P-glycoprotein, MRP1, MRP2, MRP3 and MRP5 in de novo and relapsed acute myeloid leukemia Leukemia 15 2001 1544 1553
79. D.M. van der Kolk, E.G.E. de Vries, W.L.J. van Putten, L.F. Verdonck, G.J. Ossenkoppele, and G.E.G. Verhoef P-glycoprotein and multidrug resistance protein activities in relation to treatment outcome in acute myeloid leukemia Clin. Cancer Res. 6 2000 3205 3214
80. M.A. van der Pol, J. Pater, N. Feller, A. Westra, A. van Stijn, and G. Ossenkoppele Functional characterization of minimal residual disease for P-glycoprotein and multidrug resistance protein activity in acute myeloid leukemia Leukemia 15 2001 1554 1563
81. R.B. Walter, T.A. Gooley, V.H. van der Velden, M.R. Loken, J.J. van Dongen, and D.A. Flowers CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy Blood 109 2007 4168 4170
82. E. Wattel, E. Solary, B. Hecquet, D. Caillot, N. Ifrah, and A. Brion Quinine improves the results of intensive chemotherapy in myelodysplastic syndromes expressing P glycoprotein: results of a randomized study Br. J. Haematol. 102 1998 1015 1024
83. C.S. Wilson, G.S. Davidson, S.B. Martin, E. Andries, J. Potter, and R. Harvey Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction Blood 108 2006 685 696
84. C. Wuchter, K. Leonid, V. Ruppert, M. Schrappe, T. Buchner, and C. Schoch Clinical significance of P-glycoprotein expression and function for response to induction chemotherapy, relapse rate and overall survival in acute leukemia Haematologica 85 2000 711 721
85. S. Yamanaka, and H.M. Blau Nuclear reprogramming to a pluripotent state by three approaches Nature 465 2010 704 712
86. J. Yu, M.A. Vodyanik, K. Smuga-Otto, J. Antosiewicz-Bourget, J.L. Frane, and S. Tian Induced pluripotent stem cell lines derived from human somatic cells Science 318 2007 1917 1920
87. D. Zhou, R. Zittoun, and J. Marie Expression of multidrug resistance-associate protein (MRP) and multidrug resistance (MDR1) genes in acute myeloid leukemia Leukemia 9 1995 1661 1666
88. S. Zhou, Y. Zong, T. Lu, and B.P. Sorrentino Hematopoietic cells from mice that are deficient in both Bcrp1/Abcg2 and Mdr1a/1b develop normally but are sensitized to mitoxantrone Biotechniques 35 2003 1248 1252